ENTPD1 and head and neck cancer: CD103+CD39+ TILs could serve as a potential biomarker of anti-OX40 clinical activity in patients with head and neck cancer, and might represent a biomarker of RFS following anti-PD-1 therapy in melanoma (63, 64).